Paula Stroian
Paula Stroian is a PhD candidate at Babes-Bolyai University in Cluj-Napoca. Her research interests include the use of schema therapy techniques in depression and social anxiety. Paula Stroian is also part of the international consortium dedicated to validating the new versions of the Schema Mode Inventory and Young Schema Questionnaire. Moreover, Paula Stroian is a certified clinical psychologist and psychotherapist in cognitive behavioral therapy, and have undergone schema therapy training while currently under supervision in this approach. She currently practices cognitive schema therapy with clients with emotional and personality disorders.
nCompass
Given the high prevalence of depression, the need for increasing treatment accessibility for this psychological problem is evident. The aim of this study was to test the feasibility, acceptability and outcomes of nCompass, a brief self-help ST-enhanced behavioral activation program for depressive symptoms. 144 participants, recruited online, scoring 14 or higher on the Beck Depression Inventory, were enrolled in either the 15-day mobile program or an active control (psychoeducation) group. Participants filled in instruments assessing depressive symptoms, self-compassion, maladaptive coping and well-being at baseline, immediately following the program and at a two-week follow-up. Participants in the nCompass group also filled in acceptability measures at post-test. Out of the 72 participants allocated to the nCompass group, 45 (62,5%) completed the intervention. The nCompass intervention was found to be acceptable, with the majority of participants rating it high or very high on most dimensions. Significant improvements were found in terms of depressive symptoms and Surrender coping in the nCompass group, compared to the active control. The effects of the mobile intervention on depressive symptoms were explained by reductions in Surrender coping. The results point to the utility of the nCompass intervention for individuals with depression, in terms of decreasing symptomatology and maladaptive coping. Furthermore, the high acceptability rates suggest that nCompass can be an attractive treatment option for depressed individuals.